Chai Discovery nabs $400M Series C as AI-designed antibodies reach Big Pharma
, a company that develops artificial intelligence models to predict interactions between biochemical molecules, today announced it has raised $400 million in new funding, nearly tripling its valuation to $3. Index Ventures led the Series C round alongside Kleiner Perkins, Sequoia Capital and Dimension. New investors joining the investment included Bain Capital [...
Key Takeaways
- SiliconANGLE UPDATED 11:40 EDT / JULY 14 2026 AI Chai Discovery nabs $400M Series C as AI-designed antibodies reach Big Pharma by Kyt Dotson Chai Discovery Inc.
New investors joining the investment included Bain Capital Ventures, Battery Ventures, Baillie Gifford, BDT & MSD, Sapphire Ventures, Avra Capital and other notable investors.
- "Tomorrow's medicines should be designed with the precision, speed and scale of modern engineering, and this support helps us move faster towards that future," said co-founder and Chief Executive Joshua Meier.
- The old way of discovering which ones worked involved screening millions of potential molecules and testing them one by one.
To tackle this problem, Chai created an AI system that can perform rapid simulations based on disease targets to design a molecule that fits correctly.
- and formed a formal collaboration with the Swiss multinational drug company Novartis AG .
Chai faces a very real climb within the drug discovery industry.
- Ideally, drug discovery and life sciences will need to overcome this hurdle by gaining a better understanding of candidates and their effects as they advance into clinical trials.
Stats & Key Facts
- #, a company that develops artificial intelligence models to predict interactions between biochemical molecules, today announced it has raised $400 million in new funding, nearly tripling its valuation to $3.
- #] The post Chai Discovery nabs $400M Series C as AI-designed antibodies reach Big Pharma appeared first on SiliconANGLE.
- #SiliconANGLE UPDATED 11:40 EDT / JULY 14 2026 AI Chai Discovery nabs $400M Series C as AI-designed antibodies reach Big Pharma by Kyt Dotson Chai Discovery Inc.
- #, a company that develops artificial intelligence models to predict interactions between biochemical molecules, today announced it has raised $400 million in new funding, nearly tripling its valuation to $3.
SiliconANGLE UPDATED 11:40 EDT / JULY 14 2026 AI Chai Discovery nabs $400M Series C as AI-designed antibodies reach Big Pharma by Kyt Dotson Chai Discovery Inc. , a company that develops artificial intelligence models to predict interactions between biochemical molecules, today announced it has raised $400 million in new funding, nearly tripling its valuation to $3. Index Ventures led the Series C round alongside Kleiner Perkins, Sequoia Capital and Dimension.
New investors joining the investment included Bain Capital Ventures, Battery Ventures, Baillie Gifford, BDT & MSD, Sapphire Ventures, Avra Capital and other notable investors. Existing investors included Thrive Capital, OpenAI, Oak HC/FT, Menlo Ventures and General Catalyst, among others. The round raises the company's total funding to about $630 million to date, including $130 million at a $1.
3 billion valuation in December. Chai Discovery builds frontier AI models designed to accelerate drug discovery. They act by predicting and reprogramming molecular interactions, a necessary first step toward fully understanding how chemistry works for pharmaceutical and life sciences companies.
For more details please read the original article at SiliconANGLE AI.
Continue Learning
Comments
Sign in to join the conversation